ACE2 and COVID-19: However, in a Phase 1 clinical trial (ClinicalTrials.gov identifier: NCT04583228), HLX71, a recombinant human angiotensin-converting enzyme 2 (ACE2)-Fc fusion protein developed for COVID-19, showed good safety and tolerability in healthy adult subjects.